{"transactions":[{"id":4614038,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2479,"kind":"organization","name":"MPM BioVentures 2014, L.P.","position":1,"cik":"0001609492","reported_name":"MPM BioVentures 2014, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2480,"kind":"person","name":"EVNIN LUKE","position":2,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":3,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2482,"kind":"person","name":"Foley Todd","position":4,"cik":"0001473930","reported_name":"Foley Todd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2483,"kind":"organization","name":"MPM BioVentures 2014 (B), L.P.","position":5,"cik":"0001609493","reported_name":"MPM BioVentures 2014 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2484,"kind":"organization","name":"MPM Asset Management Investors BV2014 LLC","position":6,"cik":"0001609495","reported_name":"MPM Asset Management Investors BV2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2485,"kind":"organization","name":"MPM BioVentures 2014 LLC","position":7,"cik":"0001765021","reported_name":"MPM BioVentures 2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2486,"kind":"organization","name":"MPM BioVentures 2014 GP LLC","position":8,"cik":"0001765091","reported_name":"MPM BioVentures 2014 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2487,"kind":"organization","name":"MPM BIOVENTURES 2018 (B), L.P.","position":9,"cik":"0001729504","reported_name":"MPM BIOVENTURES 2018 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2488,"kind":"organization","name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","position":10,"cik":"0001734817","reported_name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-09T23:23:33.000Z","date":"2026-09-09","kind":"sale","planned":false,"acquired":false,"shares":28837,"price":7.13,"value":205607.81,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F8","text":"The shares were sold as follows: 13,095 by BV 2014, 873 by BV 2014(B), 451 by AM BV2014, 13,439 by BV 2018, 714 by BV 2018(B) and 265 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.02 to $7.54 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding\nthe number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The shares are held as follows: 1,764,167 by BV 2014, 117,667 by BV 2014(B), 60,722 by AM BV2014, 1,810,592 by BV 2018, 96,232 by BV 2018(B) and 35,735  by AM BV2018."}],"balance_after":3885115,"source":{"system":"sec-edgar","filing":"0001231919-26-001155","document":"form4-09092026_110922.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1765091/000123191926001155/form4-09092026_110922.xml","form_type":"4"}},{"id":4614037,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2479,"kind":"organization","name":"MPM BioVentures 2014, L.P.","position":1,"cik":"0001609492","reported_name":"MPM BioVentures 2014, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2480,"kind":"person","name":"EVNIN LUKE","position":2,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":3,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2482,"kind":"person","name":"Foley Todd","position":4,"cik":"0001473930","reported_name":"Foley Todd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2483,"kind":"organization","name":"MPM BioVentures 2014 (B), L.P.","position":5,"cik":"0001609493","reported_name":"MPM BioVentures 2014 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2484,"kind":"organization","name":"MPM Asset Management Investors BV2014 LLC","position":6,"cik":"0001609495","reported_name":"MPM Asset Management Investors BV2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2485,"kind":"organization","name":"MPM BioVentures 2014 LLC","position":7,"cik":"0001765021","reported_name":"MPM BioVentures 2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2486,"kind":"organization","name":"MPM BioVentures 2014 GP LLC","position":8,"cik":"0001765091","reported_name":"MPM BioVentures 2014 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2487,"kind":"organization","name":"MPM BIOVENTURES 2018 (B), L.P.","position":9,"cik":"0001729504","reported_name":"MPM BIOVENTURES 2018 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2488,"kind":"organization","name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","position":10,"cik":"0001734817","reported_name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-09T23:23:33.000Z","date":"2026-09-08","kind":"sale","planned":false,"acquired":false,"shares":192500,"price":7.41,"value":1426425.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"The shares were sold as follows: 87,411 by BV 2014, 5,830 by BV 2014(B), 3,009 by AM BV2014, 89,712 by BV 2018, 4,768 by BV 2018(B) and 1,770 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.97 to $7.70 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are held as follows: 1,777,262 by BV 2014, 118,540 by BV 2014(B), 61,173 by AM BV2014, 1,824,031 by BV 2018, 96,946 by BV 2018(B) and 36,000 by AM BV2018."}],"balance_after":3913952,"source":{"system":"sec-edgar","filing":"0001231919-26-001155","document":"form4-09092026_110922.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1765091/000123191926001155/form4-09092026_110922.xml","form_type":"4"}},{"id":4614036,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2479,"kind":"organization","name":"MPM BioVentures 2014, L.P.","position":1,"cik":"0001609492","reported_name":"MPM BioVentures 2014, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2480,"kind":"person","name":"EVNIN LUKE","position":2,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":3,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2482,"kind":"person","name":"Foley Todd","position":4,"cik":"0001473930","reported_name":"Foley Todd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2483,"kind":"organization","name":"MPM BioVentures 2014 (B), L.P.","position":5,"cik":"0001609493","reported_name":"MPM BioVentures 2014 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2484,"kind":"organization","name":"MPM Asset Management Investors BV2014 LLC","position":6,"cik":"0001609495","reported_name":"MPM Asset Management Investors BV2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2485,"kind":"organization","name":"MPM BioVentures 2014 LLC","position":7,"cik":"0001765021","reported_name":"MPM BioVentures 2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2486,"kind":"organization","name":"MPM BioVentures 2014 GP LLC","position":8,"cik":"0001765091","reported_name":"MPM BioVentures 2014 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2487,"kind":"organization","name":"MPM BIOVENTURES 2018 (B), L.P.","position":9,"cik":"0001729504","reported_name":"MPM BIOVENTURES 2018 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2488,"kind":"organization","name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","position":10,"cik":"0001734817","reported_name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-09T23:23:33.000Z","date":"2026-09-04","kind":"sale","planned":false,"acquired":false,"shares":38500,"price":7.11,"value":273735.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were sold as follows: 17,482 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 1,166 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 602 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 17,942 by MPM BioVentures 2018, L.P. (\"BV 2018\"), 954 by MPM BioVentures 2018 (B), L.P. (\"BV 2018(B)\") and 354 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV2014 LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.01 to $7.16 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held as follows: 1,864,673 by BV 2014, 124,370 by BV 2014(B), 64,182 by AM BV2014, 1,913,743 by BV 2018, 101,714 by BV 2018(B) and 37,770 by AM BV2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."}],"balance_after":4106452,"source":{"system":"sec-edgar","filing":"0001231919-26-001155","document":"form4-09092026_110922.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1765091/000123191926001155/form4-09092026_110922.xml","form_type":"4"}},{"id":3645,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2479,"kind":"organization","name":"MPM BioVentures 2014, L.P.","position":1,"cik":"0001609492","reported_name":"MPM BioVentures 2014, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2480,"kind":"person","name":"EVNIN LUKE","position":2,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":3,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2482,"kind":"person","name":"Foley Todd","position":4,"cik":"0001473930","reported_name":"Foley Todd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2483,"kind":"organization","name":"MPM BioVentures 2014 (B), L.P.","position":5,"cik":"0001609493","reported_name":"MPM BioVentures 2014 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2484,"kind":"organization","name":"MPM Asset Management Investors BV2014 LLC","position":6,"cik":"0001609495","reported_name":"MPM Asset Management Investors BV2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2485,"kind":"organization","name":"MPM BioVentures 2014 LLC","position":7,"cik":"0001765021","reported_name":"MPM BioVentures 2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2486,"kind":"organization","name":"MPM BioVentures 2014 GP LLC","position":8,"cik":"0001765091","reported_name":"MPM BioVentures 2014 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2487,"kind":"organization","name":"MPM BIOVENTURES 2018 (B), L.P.","position":9,"cik":"0001729504","reported_name":"MPM BIOVENTURES 2018 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2488,"kind":"organization","name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","position":10,"cik":"0001734817","reported_name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-03T23:21:03.000Z","date":"2026-09-03","kind":"sale","planned":false,"acquired":false,"shares":32263,"price":7.17,"value":231325.71,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F8","text":"The shares were sold as follows: 14,650 by BV 2014, 977 by BV 2014(B), 504 by AM BV2014, 15,036 by BV 2018, 799 by BV 2018(B) and 297 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.0434 to $7.405 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding\nthe number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The shares are held as follows: 1,882,155 by BV 2014, 125,536 by BV 2014(B), 64,784 by AM BV2014, 1,931,685 by BV 2018, 102,668 by BV 2018(B) and 38,124 by AM BV2018."}],"balance_after":4144952,"source":{"system":"sec-edgar","filing":"0001231919-26-001143","document":"form4-09032026_110951.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1765091/000123191926001143/form4-09032026_110951.xml","form_type":"4"}},{"id":3644,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2479,"kind":"organization","name":"MPM BioVentures 2014, L.P.","position":1,"cik":"0001609492","reported_name":"MPM BioVentures 2014, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2480,"kind":"person","name":"EVNIN LUKE","position":2,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":3,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2482,"kind":"person","name":"Foley Todd","position":4,"cik":"0001473930","reported_name":"Foley Todd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2483,"kind":"organization","name":"MPM BioVentures 2014 (B), L.P.","position":5,"cik":"0001609493","reported_name":"MPM BioVentures 2014 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2484,"kind":"organization","name":"MPM Asset Management Investors BV2014 LLC","position":6,"cik":"0001609495","reported_name":"MPM Asset Management Investors BV2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2485,"kind":"organization","name":"MPM BioVentures 2014 LLC","position":7,"cik":"0001765021","reported_name":"MPM BioVentures 2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2486,"kind":"organization","name":"MPM BioVentures 2014 GP LLC","position":8,"cik":"0001765091","reported_name":"MPM BioVentures 2014 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2487,"kind":"organization","name":"MPM BIOVENTURES 2018 (B), L.P.","position":9,"cik":"0001729504","reported_name":"MPM BIOVENTURES 2018 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2488,"kind":"organization","name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","position":10,"cik":"0001734817","reported_name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-03T23:21:03.000Z","date":"2026-09-02","kind":"sale","planned":false,"acquired":false,"shares":25131,"price":7.19,"value":180691.89,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"The shares were sold as follows: 11,412 by BV 2014, 761 by BV 2014(B), 393 by AM BV2014, 11,712 by BV 2018, 622 by BV 2018(B) and 231 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.9601 to $7.3273 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are held as follows: 1,896,805 by BV 2014, 126,513 by BV 2014(B), 65,288 by AM BV2014, 1,946,721 by BV 2018, 103,467 by BV 2018(B) and 38,421 by AM BV2018."}],"balance_after":4177215,"source":{"system":"sec-edgar","filing":"0001231919-26-001143","document":"form4-09032026_110951.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1765091/000123191926001143/form4-09032026_110951.xml","form_type":"4"}},{"id":3643,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2479,"kind":"organization","name":"MPM BioVentures 2014, L.P.","position":1,"cik":"0001609492","reported_name":"MPM BioVentures 2014, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2480,"kind":"person","name":"EVNIN LUKE","position":2,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":3,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2482,"kind":"person","name":"Foley Todd","position":4,"cik":"0001473930","reported_name":"Foley Todd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2483,"kind":"organization","name":"MPM BioVentures 2014 (B), L.P.","position":5,"cik":"0001609493","reported_name":"MPM BioVentures 2014 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2484,"kind":"organization","name":"MPM Asset Management Investors BV2014 LLC","position":6,"cik":"0001609495","reported_name":"MPM Asset Management Investors BV2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2485,"kind":"organization","name":"MPM BioVentures 2014 LLC","position":7,"cik":"0001765021","reported_name":"MPM BioVentures 2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2486,"kind":"organization","name":"MPM BioVentures 2014 GP LLC","position":8,"cik":"0001765091","reported_name":"MPM BioVentures 2014 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2487,"kind":"organization","name":"MPM BIOVENTURES 2018 (B), L.P.","position":9,"cik":"0001729504","reported_name":"MPM BIOVENTURES 2018 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2488,"kind":"organization","name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","position":10,"cik":"0001734817","reported_name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-03T23:21:03.000Z","date":"2026-09-01","kind":"sale","planned":false,"acquired":false,"shares":29088,"price":7.06,"value":205361.28,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were sold as follows: 13,208 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 881 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 455 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 13,556 by MPM BioVentures 2018, L.P. (\"BV 2018\"), 720 by MPM BioVentures 2018 (B), L.P. (\"BV 2018(B)\") and 268 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV2014 LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.80 to $7.15 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held as follows: 1,908,217 by BV 2014, 127,274 by BV 2014(B), 65,681 by AM BV2014, 1,958,433 by BV 2018, 104,089 by BV 2018(B) and 38,652 by AM BV2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."}],"balance_after":4202346,"source":{"system":"sec-edgar","filing":"0001231919-26-001143","document":"form4-09032026_110951.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1765091/000123191926001143/form4-09032026_110951.xml","form_type":"4"}},{"id":672221,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2479,"kind":"organization","name":"MPM BioVentures 2014, L.P.","position":1,"cik":"0001609492","reported_name":"MPM BioVentures 2014, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2480,"kind":"person","name":"EVNIN LUKE","position":2,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":3,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2482,"kind":"person","name":"Foley Todd","position":4,"cik":"0001473930","reported_name":"Foley Todd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2483,"kind":"organization","name":"MPM BioVentures 2014 (B), L.P.","position":5,"cik":"0001609493","reported_name":"MPM BioVentures 2014 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2484,"kind":"organization","name":"MPM Asset Management Investors BV2014 LLC","position":6,"cik":"0001609495","reported_name":"MPM Asset Management Investors BV2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2485,"kind":"organization","name":"MPM BioVentures 2014 LLC","position":7,"cik":"0001765021","reported_name":"MPM BioVentures 2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2486,"kind":"organization","name":"MPM BioVentures 2014 GP LLC","position":8,"cik":"0001765091","reported_name":"MPM BioVentures 2014 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2487,"kind":"organization","name":"MPM BIOVENTURES 2018 (B), L.P.","position":9,"cik":"0001729504","reported_name":"MPM BIOVENTURES 2018 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2488,"kind":"organization","name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","position":10,"cik":"0001734817","reported_name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-31T22:25:04.000Z","date":"2026-08-31","kind":"sale","planned":false,"acquired":false,"shares":44259,"price":6.99,"value":309370.41,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F8","text":"The shares were sold as follows: 20,097 by BV 2014, 1,341 by BV 2014(B), 692 by AM BV2014, 20,626 by BV 2018, 1,096 by BV 2018(B) and 407 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.76 to $7.1626 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The shares are held as follows: 1,921,425 by BV 2014, 128,155 by BV 2014(B), 66,136 by AM BV2014, 1,971,989 by BV 2018, 104,809 by BV 2018(B) and 38,920 by AM BV2018."}],"balance_after":4231434,"source":{"system":"sec-edgar","filing":"0001231919-26-001135","document":"form4-08312026_100852.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191926001135/form4-08312026_100852.xml","form_type":"4"}},{"id":672220,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2479,"kind":"organization","name":"MPM BioVentures 2014, L.P.","position":1,"cik":"0001609492","reported_name":"MPM BioVentures 2014, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2480,"kind":"person","name":"EVNIN LUKE","position":2,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":3,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2482,"kind":"person","name":"Foley Todd","position":4,"cik":"0001473930","reported_name":"Foley Todd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2483,"kind":"organization","name":"MPM BioVentures 2014 (B), L.P.","position":5,"cik":"0001609493","reported_name":"MPM BioVentures 2014 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2484,"kind":"organization","name":"MPM Asset Management Investors BV2014 LLC","position":6,"cik":"0001609495","reported_name":"MPM Asset Management Investors BV2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2485,"kind":"organization","name":"MPM BioVentures 2014 LLC","position":7,"cik":"0001765021","reported_name":"MPM BioVentures 2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2486,"kind":"organization","name":"MPM BioVentures 2014 GP LLC","position":8,"cik":"0001765091","reported_name":"MPM BioVentures 2014 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2487,"kind":"organization","name":"MPM BIOVENTURES 2018 (B), L.P.","position":9,"cik":"0001729504","reported_name":"MPM BIOVENTURES 2018 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2488,"kind":"organization","name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","position":10,"cik":"0001734817","reported_name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-31T22:25:04.000Z","date":"2026-08-28","kind":"sale","planned":false,"acquired":false,"shares":3733,"price":7.01,"value":26168.33,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"The shares were sold as follows: 1,695 by BV 2014, 113 by BV 2014(B), 58 by AM BV2014, 1,740 by BV 2018, 93 by BV 2018(B) and 34 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.95 to $7.24 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are held as follows: 1,941,522 by BV 2014, 129,496 by BV 2014(B), 66,828 by AM BV2014, 1,992,615 by BV 2018, 105,905 by BV 2018(B) and 39,327 by AM BV2018."}],"balance_after":4275693,"source":{"system":"sec-edgar","filing":"0001231919-26-001135","document":"form4-08312026_100852.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191926001135/form4-08312026_100852.xml","form_type":"4"}},{"id":672219,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2479,"kind":"organization","name":"MPM BioVentures 2014, L.P.","position":1,"cik":"0001609492","reported_name":"MPM BioVentures 2014, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2480,"kind":"person","name":"EVNIN LUKE","position":2,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":3,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2482,"kind":"person","name":"Foley Todd","position":4,"cik":"0001473930","reported_name":"Foley Todd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2483,"kind":"organization","name":"MPM BioVentures 2014 (B), L.P.","position":5,"cik":"0001609493","reported_name":"MPM BioVentures 2014 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2484,"kind":"organization","name":"MPM Asset Management Investors BV2014 LLC","position":6,"cik":"0001609495","reported_name":"MPM Asset Management Investors BV2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2485,"kind":"organization","name":"MPM BioVentures 2014 LLC","position":7,"cik":"0001765021","reported_name":"MPM BioVentures 2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2486,"kind":"organization","name":"MPM BioVentures 2014 GP LLC","position":8,"cik":"0001765091","reported_name":"MPM BioVentures 2014 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2487,"kind":"organization","name":"MPM BIOVENTURES 2018 (B), L.P.","position":9,"cik":"0001729504","reported_name":"MPM BIOVENTURES 2018 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2488,"kind":"organization","name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","position":10,"cik":"0001734817","reported_name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-31T22:25:04.000Z","date":"2026-08-27","kind":"sale","planned":false,"acquired":false,"shares":38922,"price":7.2,"value":280238.4,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were sold as follows: 17,674 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 1,179 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 608 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 18,139 by MPM BioVentures 2018, L.P. (\"BV 2018\"), 964 by MPM BioVentures 2018 (B), L.P. (\"BV 2018(B)\") and 358 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV2014 LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.88 to $7.37 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held as follows: 1,943,217 by BV 2014, 129,609 by BV 2014(B), 66,886 by AM BV2014, 1,994,355 by BV 2018, 105,998 by BV 2018(B) and 39,361 by AM BV2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."}],"balance_after":4279426,"source":{"system":"sec-edgar","filing":"0001231919-26-001135","document":"form4-08312026_100852.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191926001135/form4-08312026_100852.xml","form_type":"4"}},{"id":675339,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2479,"kind":"organization","name":"MPM BioVentures 2014, L.P.","position":1,"cik":"0001609492","reported_name":"MPM BioVentures 2014, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2480,"kind":"person","name":"EVNIN LUKE","position":2,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":3,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2482,"kind":"person","name":"Foley Todd","position":4,"cik":"0001473930","reported_name":"Foley Todd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2483,"kind":"organization","name":"MPM BioVentures 2014 (B), L.P.","position":5,"cik":"0001609493","reported_name":"MPM BioVentures 2014 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2484,"kind":"organization","name":"MPM Asset Management Investors BV2014 LLC","position":6,"cik":"0001609495","reported_name":"MPM Asset Management Investors BV2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2485,"kind":"organization","name":"MPM BioVentures 2014 LLC","position":7,"cik":"0001765021","reported_name":"MPM BioVentures 2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2486,"kind":"organization","name":"MPM BioVentures 2014 GP LLC","position":8,"cik":"0001765091","reported_name":"MPM BioVentures 2014 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2487,"kind":"organization","name":"MPM BIOVENTURES 2018 (B), L.P.","position":9,"cik":"0001729504","reported_name":"MPM BIOVENTURES 2018 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2488,"kind":"organization","name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","position":10,"cik":"0001734817","reported_name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-27T01:28:15.000Z","date":"2026-08-26","kind":"sale","planned":false,"acquired":false,"shares":14569,"price":7.06,"value":102857.14,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F8","text":"The shares were sold as follows: 6,615 by BV 2014, 441 by BV 2014(B), 228 by AM BV2014, 6,790 by BV 2018, 361 by BV 2018(B) and 134 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.97 to $7.55 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The shares are held as follows: 1,960,891 by BV 2014, 130,788 by BV 2014(B), 67,494 by AM BV2014, 2,012,494 by BV 2018, 106,962 by BV 2018(B) and 39,719 by AM BV2018."}],"balance_after":4318348,"source":{"system":"sec-edgar","filing":"0001231919-26-001107","document":"form4-08272026_010802.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191926001107/form4-08272026_010802.xml","form_type":"4"}},{"id":675338,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2479,"kind":"organization","name":"MPM BioVentures 2014, L.P.","position":1,"cik":"0001609492","reported_name":"MPM BioVentures 2014, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2480,"kind":"person","name":"EVNIN LUKE","position":2,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":3,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2482,"kind":"person","name":"Foley Todd","position":4,"cik":"0001473930","reported_name":"Foley Todd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2483,"kind":"organization","name":"MPM BioVentures 2014 (B), L.P.","position":5,"cik":"0001609493","reported_name":"MPM BioVentures 2014 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2484,"kind":"organization","name":"MPM Asset Management Investors BV2014 LLC","position":6,"cik":"0001609495","reported_name":"MPM Asset Management Investors BV2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2485,"kind":"organization","name":"MPM BioVentures 2014 LLC","position":7,"cik":"0001765021","reported_name":"MPM BioVentures 2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2486,"kind":"organization","name":"MPM BioVentures 2014 GP LLC","position":8,"cik":"0001765091","reported_name":"MPM BioVentures 2014 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2487,"kind":"organization","name":"MPM BIOVENTURES 2018 (B), L.P.","position":9,"cik":"0001729504","reported_name":"MPM BIOVENTURES 2018 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2488,"kind":"organization","name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","position":10,"cik":"0001734817","reported_name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-27T01:28:15.000Z","date":"2026-08-25","kind":"sale","planned":false,"acquired":false,"shares":26522,"price":7.54,"value":199975.88,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"The shares were sold as follows: 12,043 by BV 2014, 803 by BV 2014(B), 415 by AM BV2014, 12,360 by BV 2018, 657 by BV 2018(B) and 244 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.28 to $7.6421 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are held as follows: 1,967,506 by BV 2014, 131,229 by BV 2014(B), 67,722 by AM BV2014, 2,019,284 by BV 2018, 107,323 by BV 2018(B) and 39,853 by AM BV2018."}],"balance_after":4332917,"source":{"system":"sec-edgar","filing":"0001231919-26-001107","document":"form4-08272026_010802.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191926001107/form4-08272026_010802.xml","form_type":"4"}},{"id":675337,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2479,"kind":"organization","name":"MPM BioVentures 2014, L.P.","position":1,"cik":"0001609492","reported_name":"MPM BioVentures 2014, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2480,"kind":"person","name":"EVNIN LUKE","position":2,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":3,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2482,"kind":"person","name":"Foley Todd","position":4,"cik":"0001473930","reported_name":"Foley Todd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2483,"kind":"organization","name":"MPM BioVentures 2014 (B), L.P.","position":5,"cik":"0001609493","reported_name":"MPM BioVentures 2014 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2484,"kind":"organization","name":"MPM Asset Management Investors BV2014 LLC","position":6,"cik":"0001609495","reported_name":"MPM Asset Management Investors BV2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2485,"kind":"organization","name":"MPM BioVentures 2014 LLC","position":7,"cik":"0001765021","reported_name":"MPM BioVentures 2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2486,"kind":"organization","name":"MPM BioVentures 2014 GP LLC","position":8,"cik":"0001765091","reported_name":"MPM BioVentures 2014 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2487,"kind":"organization","name":"MPM BIOVENTURES 2018 (B), L.P.","position":9,"cik":"0001729504","reported_name":"MPM BIOVENTURES 2018 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2488,"kind":"organization","name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","position":10,"cik":"0001734817","reported_name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-27T01:28:15.000Z","date":"2026-08-24","kind":"sale","planned":false,"acquired":false,"shares":21623,"price":7.34,"value":158712.82,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were sold as follows: 9,819 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 655 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 338 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 10,077 by MPM BioVentures 2018, L.P. (\"BV 2018\"), 535 by MPM BioVentures 2018 (B), L.P. (\"BV 2018(B)\") and 199 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV2014 LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.0852 to $7.58 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held as follows: 1,979,549 by BV 2014, 132,032 by BV 2014(B), 68,137 by AM BV2014, 2,031,644 by BV 2018, 107,980 by BV 2018(B) and 40,097 by AM BV2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."}],"balance_after":4359439,"source":{"system":"sec-edgar","filing":"0001231919-26-001107","document":"form4-08272026_010802.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191926001107/form4-08272026_010802.xml","form_type":"4"}},{"id":939526,"issuer":{"id":4711,"kind":"organization","name":"Aktis Oncology, Inc.","symbol":"AKTS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":2,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69401,"kind":"organization","name":"Oncology Impact Private Investment Fund 2, L.P.","position":3,"cik":"0002104306","reported_name":"Oncology Impact Private Investment Fund 2, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Redeemable Convertible Preferred Stock","published_at":"2026-01-14T23:17:54.000Z","date":"2026-01-12","kind":"exercise","planned":false,"acquired":false,"shares":6000000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares of common stock were issued upon conversion as follows:  668,173 by BV 2018, 35,512 by BV 2018(B), 13,187 by AM BV2018, 143,374 by MPM Oncology and 716,873 by MPM Oncology Impact."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1577119},"source":{"system":"sec-edgar","filing":"0001231919-26-000055","document":"form4-01142026_110148.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191926000055/form4-01142026_110148.xml","form_type":"4"}},{"id":939525,"issuer":{"id":4711,"kind":"organization","name":"Aktis Oncology, Inc.","symbol":"AKTS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":2,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69401,"kind":"organization","name":"Oncology Impact Private Investment Fund 2, L.P.","position":3,"cik":"0002104306","reported_name":"Oncology Impact Private Investment Fund 2, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Redeemable Convertible Preferred Stock","published_at":"2026-01-14T23:17:54.000Z","date":"2026-01-12","kind":"exercise","planned":false,"acquired":false,"shares":22500000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares of common stock were issued upon conversion as follows:  2,505,648 by BV 2018, 133,170 by BV 2018(B), 49,452 by AM BV2018, 537,654 by MPM Oncology and 2,688,273 by MPM Oncology Impact."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":5914197},"source":{"system":"sec-edgar","filing":"0001231919-26-000055","document":"form4-01142026_110148.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191926000055/form4-01142026_110148.xml","form_type":"4"}},{"id":939524,"issuer":{"id":4711,"kind":"organization","name":"Aktis Oncology, Inc.","symbol":"AKTS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":2,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69401,"kind":"organization","name":"Oncology Impact Private Investment Fund 2, L.P.","position":3,"cik":"0002104306","reported_name":"Oncology Impact Private Investment Fund 2, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series Seed Redeemable Convertible Preferred Stock","published_at":"2026-01-14T23:17:54.000Z","date":"2026-01-12","kind":"exercise","planned":false,"acquired":false,"shares":5000000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares of common stock were issued upon conversion as follows: 556,810 by MPM BioVentures 2018, L.P. (\"BV 2018\"), 29,593 by MPM BioVentures 2018 (B), L.P. (\"BV 2018(B)\"), 10,988 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\"), 119,478 by MPM Oncology Innovations\nFund, L.P. (\"MPM Oncology\") and 597,393 by Oncology Impact Private Investment Fund 2, L.P. (\"MPM Oncology Impact\"). MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV2018 LLC\") are the direct and indirect general partners of BV 2018 and\nBV 2018(B). BV 2018 LLC is the manager of AM BV2018. Drs. Evnin and Gadicke are managing directors of BV 2018 LLC and managers of MPM Oncology Innovations Fund GP LLC, which is the general partner of MPM Oncology. Dr. Gadicke is the managing\nmember of MPM Oncology Investments 2 LLC, which is the general partner of MPM Oncology Impact."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1314262},"source":{"system":"sec-edgar","filing":"0001231919-26-000055","document":"form4-01142026_110148.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191926000055/form4-01142026_110148.xml","form_type":"4"}},{"id":939523,"issuer":{"id":4711,"kind":"organization","name":"Aktis Oncology, Inc.","symbol":"AKTS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":2,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69401,"kind":"organization","name":"Oncology Impact Private Investment Fund 2, L.P.","position":3,"cik":"0002104306","reported_name":"Oncology Impact Private Investment Fund 2, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-14T23:17:54.000Z","date":"2026-01-12","kind":"purchase","planned":false,"acquired":true,"shares":1112777,"price":18,"value":20029986.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were purchased as follows: 219,897 by BV 2018, 8,689 by BV 2018(B), 4,284 by AM BV2018, 46,574 by MPM Oncology and 833,333 by MPM Oncology Impact."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The shares are held as follows: 341,709 by MPM AM, 3,950,528 by BV 2018, 206,964 by BV 2018(B), 77,911 by AM BV2018, 847,080 by MPM Oncology and 4,835,872 by MPM Oncology Impact."}],"balance_after":10260064,"source":{"system":"sec-edgar","filing":"0001231919-26-000055","document":"form4-01142026_110148.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191926000055/form4-01142026_110148.xml","form_type":"4"}},{"id":939522,"issuer":{"id":4711,"kind":"organization","name":"Aktis Oncology, Inc.","symbol":"AKTS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":2,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69401,"kind":"organization","name":"Oncology Impact Private Investment Fund 2, L.P.","position":3,"cik":"0002104306","reported_name":"Oncology Impact Private Investment Fund 2, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-14T23:17:54.000Z","date":"2026-01-12","kind":"exercise","planned":false,"acquired":true,"shares":1577119,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F7","text":"The shares of common stock were issued upon conversion as follows:  668,173 by BV 2018, 35,512 by BV 2018(B), 13,187 by AM BV2018, 143,374 by MPM Oncology and 716,873 by MPM Oncology Impact."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 341,709 by MPM AM, 3,730,631 by BV 2018, 198,275 by BV 2018(B), 73,627 by AM BV2018, 800,506 by MPM Oncology and 4,002,539 by MPM Oncology Impact."}],"balance_after":9147287,"source":{"system":"sec-edgar","filing":"0001231919-26-000055","document":"form4-01142026_110148.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191926000055/form4-01142026_110148.xml","form_type":"4"}},{"id":939521,"issuer":{"id":4711,"kind":"organization","name":"Aktis Oncology, Inc.","symbol":"AKTS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":2,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69401,"kind":"organization","name":"Oncology Impact Private Investment Fund 2, L.P.","position":3,"cik":"0002104306","reported_name":"Oncology Impact Private Investment Fund 2, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-14T23:17:54.000Z","date":"2026-01-12","kind":"exercise","planned":false,"acquired":true,"shares":5914197,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"The shares of common stock were issued upon conversion as follows:  2,505,648 by BV 2018, 133,170 by BV 2018(B), 49,452 by AM BV2018, 537,654 by MPM Oncology and 2,688,273 by MPM Oncology Impact."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are held as follows: 341,709 by MPM AM, 3,062,458 by BV 2018, 162,763 by BV 2018(B), 60,440 by AM BV2018, 657,132 by MPM Oncology and 3,285,666 by MPM Oncology Impact."}],"balance_after":7570168,"source":{"system":"sec-edgar","filing":"0001231919-26-000055","document":"form4-01142026_110148.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191926000055/form4-01142026_110148.xml","form_type":"4"}},{"id":939520,"issuer":{"id":4711,"kind":"organization","name":"Aktis Oncology, Inc.","symbol":"AKTS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":2,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69401,"kind":"organization","name":"Oncology Impact Private Investment Fund 2, L.P.","position":3,"cik":"0002104306","reported_name":"Oncology Impact Private Investment Fund 2, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-14T23:17:54.000Z","date":"2026-01-12","kind":"exercise","planned":false,"acquired":true,"shares":1314262,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of common stock were issued upon conversion as follows: 556,810 by MPM BioVentures 2018, L.P. (\"BV 2018\"), 29,593 by MPM BioVentures 2018 (B), L.P. (\"BV 2018(B)\"), 10,988 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\"), 119,478 by MPM Oncology Innovations\nFund, L.P. (\"MPM Oncology\") and 597,393 by Oncology Impact Private Investment Fund 2, L.P. (\"MPM Oncology Impact\"). MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV2018 LLC\") are the direct and indirect general partners of BV 2018 and\nBV 2018(B). BV 2018 LLC is the manager of AM BV2018. Drs. Evnin and Gadicke are managing directors of BV 2018 LLC and managers of MPM Oncology Innovations Fund GP LLC, which is the general partner of MPM Oncology. Dr. Gadicke is the managing\nmember of MPM Oncology Investments 2 LLC, which is the general partner of MPM Oncology Impact."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held as follows: 341,709 by MPM Asset Management LLC (\"MPM AM\"), 556,810 by BV 2018, 29,593 by BV 2018(B), 10,988 by AM BV2018, 119,478 by MPM Oncology and 597,393 by MPM Oncology Impact. Dr. Gadicke is the manager of MPM AM."}],"balance_after":1655971,"source":{"system":"sec-edgar","filing":"0001231919-26-000055","document":"form4-01142026_110148.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191926000055/form4-01142026_110148.xml","form_type":"4"}},{"id":980574,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2025-12-04T23:18:45.000Z","date":"2025-12-04","kind":"sale","planned":true,"acquired":false,"shares":83230,"price":0.97,"value":80733.1,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 5,714 by AM LLC, 36,101 by BV 2014, 2,408 by BV 2014(B), 1,243 by AM BV2014, 7,950 by MPM OIF and 29,814 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.92 to $1.0208 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the\nSecurities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 328,588 by AM LLC, 2,075,004 by BV 2014, 138,399 by BV 2014(B), 71,421 by AM BV2014, 454,866 by MPM OIF and 1,715,833 by UBS Oncology."}],"balance_after":4784111,"source":{"system":"sec-edgar","filing":"0001231919-25-000574","document":"form4-12042025_111237.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000574/form4-12042025_111237.xml","form_type":"4"}},{"id":980573,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2025-12-04T23:18:45.000Z","date":"2025-12-03","kind":"sale","planned":true,"acquired":false,"shares":57225,"price":0.87,"value":49785.75,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 3,929 by AM LLC, 24,821 by BV 2014, 1,656 by BV 2014(B), 854 by AM BV2014, 5,466 by MPM OIF and 20,499 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.9256 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 334,302 by AM LLC, 2,111,105 by BV 2014, 140,807 by BV 2014(B), 72,664 by AM BV2014, 462,816 by MPM OIF and 1,745,647 by UBS Oncology."}],"balance_after":4867341,"source":{"system":"sec-edgar","filing":"0001231919-25-000574","document":"form4-12042025_111237.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000574/form4-12042025_111237.xml","form_type":"4"}},{"id":980572,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2025-12-04T23:18:45.000Z","date":"2025-12-02","kind":"sale","planned":true,"acquired":false,"shares":59277,"price":0.89,"value":52756.53,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 4,070 by MPM Asset Management LLC (\"AM LLC\"), 25,712 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 1,715 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 884 by MPM Asset Management Investors BV2014 LLC (\"AM\nBV2014\"), 5,662 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\") and 21,234 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.852 to $0.9246 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 338,231 by AM LLC, 2,135,926 by BV 2014, 142,463 by BV 2014(B), 73,518 by AM BV2014, 468,282 by MPM OIF and 1,766,146 by UBS Oncology."}],"balance_after":4924566,"source":{"system":"sec-edgar","filing":"0001231919-25-000574","document":"form4-12042025_111237.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000574/form4-12042025_111237.xml","form_type":"4"}},{"id":985366,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-12-01T23:11:02.000Z","date":"2025-12-01","kind":"sale","planned":true,"acquired":false,"shares":60917,"price":0.94,"value":57261.98,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 4,182 by AM LLC, 26,423 by BV 2014, 1,762 by BV 2014(B), 910 by AM BV2014, 5,819 by MPM OIF and 21,821 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.905 to $1.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the\nSecurities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 342,301 by AM LLC, 2,161,638 by BV 2014, 144,178 by BV 2014(B), 74,402 by AM BV2014, 473,944 by MPM OIF and 1,787,380 by UBS Oncology."}],"balance_after":4983843,"source":{"system":"sec-edgar","filing":"0001231919-25-000564","document":"form4-12012025_111253.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000564/form4-12012025_111253.xml","form_type":"4"}},{"id":985365,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-12-01T23:11:02.000Z","date":"2025-11-28","kind":"sale","planned":true,"acquired":false,"shares":20277,"price":0.99,"value":20074.23,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 1,392 by AM LLC, 8,795 by BV 2014, 587 by BV 2014(B), 303 by AM BV2014, 1,937 by MPM OIF and 7,263 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9681 to $1.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 346,483 by AM LLC, 2,188,061 by BV 2014, 145,940 by BV 2014(B), 75,312 by AM BV2014, 479,763 by MPM OIF and 1,809,201 by UBS Oncology."}],"balance_after":5044760,"source":{"system":"sec-edgar","filing":"0001231919-25-000564","document":"form4-12012025_111253.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000564/form4-12012025_111253.xml","form_type":"4"}},{"id":985364,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-12-01T23:11:02.000Z","date":"2025-11-26","kind":"sale","planned":true,"acquired":false,"shares":60733,"price":0.98,"value":59518.34,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 4,170 by MPM Asset Management LLC (\"AM LLC\"), 26,343 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 1,757 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 907 by MPM Asset Management Investors BV2014 LLC (\"AM\nBV2014\"), 5,801 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\") and 21,755 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9328 to $1.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 347,875 by AM LLC, 2,196,856 by BV 2014, 146,527 by BV 2014(B), 75,615 by AM BV2014, 481,700 by MPM OIF and 1,816,464 by UBS Oncology."}],"balance_after":5065037,"source":{"system":"sec-edgar","filing":"0001231919-25-000564","document":"form4-12012025_111253.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000564/form4-12012025_111253.xml","form_type":"4"}},{"id":989048,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-25T23:03:54.000Z","date":"2025-11-25","kind":"sale","planned":true,"acquired":false,"shares":42533,"price":0.92,"value":39130.36,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 2,920 by AM LLC, 18,449 by BV 2014, 1,230 by BV 2014(B), 635 by AM BV2014, 4,063 by MPM OIF and 15,236 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.90 to $0.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the\nSecurities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 352,045 by AM LLC, 2,223,199 by BV 2014, 148,284 by BV 2014(B), 76,522 by AM BV2014, 487,501 by MPM OIF and 1,838,219 by UBS Oncology."}],"balance_after":5125770,"source":{"system":"sec-edgar","filing":"0001231919-25-000550","document":"form4-11252025_111145.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000550/form4-11252025_111145.xml","form_type":"4"}},{"id":989047,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-25T23:03:54.000Z","date":"2025-11-24","kind":"sale","planned":true,"acquired":false,"shares":88802,"price":0.98,"value":87025.96,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 6,097 by AM LLC, 38,518 by BV 2014, 2,569 by BV 2014(B), 1,325 by AM BV2014, 8,483 by MPM OIF and 31,810 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.8733 to $1.03 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 354,965 by AM LLC, 2,241,648 by BV 2014, 149,514 by BV 2014(B), 77,157 by AM BV2014, 491,564 by MPM OIF and 1,853,455 by UBS Oncology."}],"balance_after":5168303,"source":{"system":"sec-edgar","filing":"0001231919-25-000550","document":"form4-11252025_111145.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000550/form4-11252025_111145.xml","form_type":"4"}},{"id":989046,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-25T23:03:54.000Z","date":"2025-11-21","kind":"sale","planned":true,"acquired":false,"shares":64331,"price":0.83,"value":53394.73,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 4,417 by MPM Asset Management LLC (\"AM LLC\"), 27,904 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 1,861 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 960 by MPM Asset Management Investors BV2014 LLC (\"AM\nBV2014\"), 6,145 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\") and 23,044 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.80 to $0.8861 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 361,062 by AM LLC, 2,280,166 by BV 2014, 152,083 by BV 2014(B), 78,482 by AM BV2014, 500,047 by MPM OIF and 1,885,265 by UBS Oncology."}],"balance_after":5257105,"source":{"system":"sec-edgar","filing":"0001231919-25-000550","document":"form4-11252025_111145.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000550/form4-11252025_111145.xml","form_type":"4"}},{"id":992831,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-20T22:50:30.000Z","date":"2025-11-20","kind":"sale","planned":true,"acquired":false,"shares":41152,"price":0.89,"value":36625.28,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 2,825 by AM LLC, 17,850 by BV 2014, 1,191 by BV 2014(B), 614 by AM BV2014, 3,931 by MPM OIF and 14,741 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.8506 to $0.9556 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of\nthe Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 365,479 by AM LLC, 2,308,070 by BV 2014, 153,944 by BV 2014(B), 79,442 by AM BV2014, 506,192 by MPM OIF and 1,908,309 by UBS Oncology."}],"balance_after":5321436,"source":{"system":"sec-edgar","filing":"0001231919-25-000533","document":"form4-11202025_101121.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000533/form4-11202025_101121.xml","form_type":"4"}},{"id":992830,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-20T22:50:30.000Z","date":"2025-11-19","kind":"sale","planned":true,"acquired":false,"shares":66324,"price":0.94,"value":62344.56,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 4,554 by AM LLC, 28,768 by BV 2014, 1,919 by BV 2014(B), 990 by AM BV2014, 6,335 by MPM OIF and 23,758 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.901 to $0.9806 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 368,304 by AM LLC, 2,325,920 by BV 2014, 155,135 by BV 2014(B), 80,056 by AM BV2014, 510,123 by MPM OIF and 1,923,050 by UBS Oncology."}],"balance_after":5362588,"source":{"system":"sec-edgar","filing":"0001231919-25-000533","document":"form4-11202025_101121.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000533/form4-11202025_101121.xml","form_type":"4"}},{"id":992829,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-20T22:50:30.000Z","date":"2025-11-18","kind":"sale","planned":true,"acquired":false,"shares":52627,"price":0.93,"value":48943.11,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 3,613 by MPM Asset Management LLC (\"AM LLC\"), 22,827 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 1,523 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 786 by MPM Asset Management Investors BV2014 LLC (\"AM\nBV2014\"), 5,027 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\") and 18,851 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.8902 to $0.9601 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 372,858 by AM LLC, 2,354,688 by BV 2014, 157,054 by BV 2014(B), 81,046 by AM BV2014, 516,458 by MPM OIF and 1,946,808 by UBS Oncology."}],"balance_after":5428912,"source":{"system":"sec-edgar","filing":"0001231919-25-000533","document":"form4-11202025_101121.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000533/form4-11202025_101121.xml","form_type":"4"}},{"id":998125,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-18T00:20:31.000Z","date":"2025-11-17","kind":"sale","planned":true,"acquired":false,"shares":57061,"price":0.95,"value":54207.95,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 3,918 by AM LLC, 24,750 by BV 2014, 1,651 by BV 2014(B), 851 by AM BV2014, 5,451 by MPM OIF and 20,440 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9183 to $0.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 376,471 by AM LLC, 2,377,515 by BV 2014, 158,577 by BV 2014(B), 81,832 by AM BV2014, 521,485 by MPM OIF and 1,965,659 by UBS Oncology."}],"balance_after":5481539,"source":{"system":"sec-edgar","filing":"0001231919-25-000507","document":"form4-11182025_121121.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000507/form4-11182025_121121.xml","form_type":"4"}},{"id":998124,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-18T00:20:31.000Z","date":"2025-11-14","kind":"sale","planned":true,"acquired":false,"shares":61640,"price":0.93,"value":57325.2,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 4,232 by AM LLC, 26,736 by BV 2014, 1,783 by BV 2014(B), 921 by AM BV2014, 5,888 by MPM OIF and 22,080 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.895 to $0.9551 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 380,389 by AM LLC, 2,402,265 by BV 2014, 160,228 by BV 2014(B), 82,683 by AM BV2014, 526,936 by MPM OIF and 1,986,099 by UBS Oncology."}],"balance_after":5538600,"source":{"system":"sec-edgar","filing":"0001231919-25-000507","document":"form4-11182025_121121.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000507/form4-11182025_121121.xml","form_type":"4"}},{"id":998123,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-18T00:20:31.000Z","date":"2025-11-13","kind":"sale","planned":true,"acquired":false,"shares":90951,"price":0.98,"value":89131.98,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 6,244 by MPM Asset Management LLC (\"AM LLC\"), 39,450 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 2,631 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 1,359 by MPM Asset Management Investors BV2014 LLC (\"AM\nBV2014\"), 8,688 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\") and 32,579 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.918 to $1.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 384,621 by AM LLC, 2,429,001 by BV 2014, 162,011 by BV 2014(B), 83,604 by AM BV2014, 532,824 by MPM OIF and 2,008,179 by UBS Oncology."}],"balance_after":5600240,"source":{"system":"sec-edgar","filing":"0001231919-25-000507","document":"form4-11182025_121121.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000507/form4-11182025_121121.xml","form_type":"4"}},{"id":1002534,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-13T00:31:55.000Z","date":"2025-11-12","kind":"sale","planned":true,"acquired":false,"shares":40669,"price":1.09,"value":44329.21,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F12","text":"The shares were sold as follows: 2,792 by AM LLC, 17,640 by BV 2014, 1,177 by BV 2014(B), 607 by AM BV2014, 3,885 by MPM OIF and 14,568 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.065 to $1.145 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the\nSecurities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F14","text":"The shares are held as follows: 390,865 by AM LLC, 2,468,451 by BV 2014, 164,642 by BV 2014(B), 84,963 by AM BV2014, 541,512 by MPM OIF and 2,040,758 by UBS Oncology."}],"balance_after":5691191,"source":{"system":"sec-edgar","filing":"0001231919-25-000459","document":"form4-11132025_121146.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000459/form4-11132025_121146.xml","form_type":"4"}},{"id":1002533,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-13T00:31:55.000Z","date":"2025-11-11","kind":"sale","planned":true,"acquired":false,"shares":55810,"price":1.14,"value":63623.4,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 3,832 by AM LLC, 24,208 by BV 2014, 1,615 by BV 2014(B), 832 by AM BV2014, 5,331 by MPM OIF and 19,992 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.115 to $1.17 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 393,657 by AM LLC, 2,486,091 by BV 2014, 165,819 by BV 2014(B), 85,570 by AM BV2014, 545,397 by MPM OIF and 2,055,326 by UBS Oncology."}],"balance_after":5731860,"source":{"system":"sec-edgar","filing":"0001231919-25-000459","document":"form4-11132025_121146.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000459/form4-11132025_121146.xml","form_type":"4"}},{"id":1002532,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-13T00:31:55.000Z","date":"2025-11-10","kind":"sale","planned":true,"acquired":false,"shares":48570,"price":1.18,"value":57312.6,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 3,335 by AM LLC, 21,067 by BV 2014, 1,405 by BV 2014(B), 725 by AM BV2014, 4,640 by MPM OIF and 17,398 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.145 to $1.21 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 397,489 by AM LLC, 2,510,299 by BV 2014, 167,434 by BV 2014(B), 86,402 by AM BV2014, 550,728 by MPM OIF and 2,075,318 by UBS Oncology."}],"balance_after":5787670,"source":{"system":"sec-edgar","filing":"0001231919-25-000459","document":"form4-11132025_121146.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000459/form4-11132025_121146.xml","form_type":"4"}},{"id":1002531,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-13T00:31:55.000Z","date":"2025-11-07","kind":"sale","planned":true,"acquired":false,"shares":68480,"price":1.11,"value":76012.8,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 4,702 by MPM Asset Management LLC (\"AM LLC\"), 29,704 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 1,981 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 1,022 by MPM Asset Management Investors BV2014 LLC (\"AM\nBV2014\"), 6,541 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\") and 24,530 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.075 to $1.188 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the\ngeneral partner of MPM OIF. MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager\nof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 400,824 by AM LLC, 2,531,366 by BV 2014, 168,839 by BV 2014(B), 87,127 by AM BV2014, 555,368 by MPM OIF and 2,092,716 by UBS Oncology."}],"balance_after":5836240,"source":{"system":"sec-edgar","filing":"0001231919-25-000459","document":"form4-11132025_121146.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000459/form4-11132025_121146.xml","form_type":"4"}},{"id":1006039,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-07T00:40:49.000Z","date":"2025-11-06","kind":"sale","planned":true,"acquired":false,"shares":54452,"price":1.21,"value":65886.92,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 3,738 by AM LLC, 23,619 by BV 2014, 1,575 by BV 2014(B), 814 by AM BV2014, 5,201 by MPM OIF and 19,505 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.185 to $1.27 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 405,526 by AM LLC, 2,561,070 by BV 2014, 170,820 by BV 2014(B), 88,149 by AM BV2014, 561,909 by MPM OIF and 2,117,246 by UBS Oncology."}],"balance_after":5904720,"source":{"system":"sec-edgar","filing":"0001231919-25-000439","document":"form4-11072025_121138.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000439/form4-11072025_121138.xml","form_type":"4"}},{"id":1006038,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-07T00:40:49.000Z","date":"2025-11-05","kind":"sale","planned":true,"acquired":false,"shares":47950,"price":1.22,"value":58499.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 3,292 by AM LLC, 20,798 by BV 2014, 1,387 by BV 2014(B), 717 by AM BV2014, 4,580 by MPM OIF and 17,176 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.19 to $1.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 409,264 by AM LLC, 2,584,689 by BV 2014, 172,395 by BV 2014(B), 88,963 by AM BV2014, 567,110 by MPM OIF and 2,136,751 by UBS Oncology."}],"balance_after":5959172,"source":{"system":"sec-edgar","filing":"0001231919-25-000439","document":"form4-11072025_121138.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000439/form4-11072025_121138.xml","form_type":"4"}},{"id":1006037,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-07T00:40:49.000Z","date":"2025-11-04","kind":"sale","planned":true,"acquired":false,"shares":140488,"price":1.22,"value":171395.36,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 9,645 by MPM Asset Management LLC (\"AM LLC\"), 60,937 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 4,064 by MPM BioVentures 2014(B), L.P. (BV 2014(B), 2,098 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 13,420 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\") and 50,324 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC and a manager of MPM OIF GP. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"shares","element":"transactionShares","label":"F3","text":"MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.17 to $1.30 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 412,556 by AM LLC, 2,605,487 by BV 2014, 173,782 by BV 2014(B), 89,680 by AM BV2014, 571,690 by MPM OIF and 2,153,927 by UBS Oncology."}],"balance_after":6007122,"source":{"system":"sec-edgar","filing":"0001231919-25-000439","document":"form4-11072025_121138.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000439/form4-11072025_121138.xml","form_type":"4"}},{"id":1009818,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-04T00:07:07.000Z","date":"2025-11-03","kind":"sale","planned":true,"acquired":false,"shares":94063,"price":1.29,"value":121341.27,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 6,458 by AM LLC, 40,800 by BV 2014, 2,721 by BV 2014(B), 1,405 by AM BV2014, 8,985 by MPM OIF and 33,694 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.245 to $1.33 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 422,201 by AM LLC, 2,666,424 by BV 2014, 177,846 by BV 2014(B), 91,778 by AM BV2014, 585,110 by MPM OIF and 2,204,251 by UBS Oncology."}],"balance_after":6147610,"source":{"system":"sec-edgar","filing":"0001231919-25-000404","document":"form4-11042025_121157.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000404/form4-11042025_121157.xml","form_type":"4"}},{"id":1009817,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-04T00:07:07.000Z","date":"2025-10-31","kind":"sale","planned":true,"acquired":false,"shares":114044,"price":1.28,"value":145976.32,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 7,830 by AM LLC, 49,467 by BV 2014, 3,299 by BV 2014(B), 1,702 by AM BV2014, 10,894 by MPM OIF and 40,852 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.205 to $1.415 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 428,659 by AM LLC, 2,707,224 by BV 2014, 180,567 by BV 2014(B), 93,183 by AM BV2014, 594,095 by MPM OIF and 2,237,945 by UBS Oncology."}],"balance_after":6241673,"source":{"system":"sec-edgar","filing":"0001231919-25-000404","document":"form4-11042025_121157.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000404/form4-11042025_121157.xml","form_type":"4"}},{"id":1009816,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-04T00:07:07.000Z","date":"2025-10-30","kind":"sale","planned":true,"acquired":false,"shares":86936,"price":1.43,"value":124318.48,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 5,969 by MPM Asset Management LLC (\"AM LLC\"), 37,709 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 2,515 by MPM BioVentures 2014(B), L.P. (BV 2014(B), 1,298 MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 8,304 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\") and 31,141 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC and a manager of MPM OIF GP. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"shares","element":"transactionShares","label":"F3","text":"MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.365 to $1.55 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 436,489 by AM LLC, 2,756,691 by BV 2014, 183,866 by BV 2014(B), 94,885 by AM BV2014, 604,989 by MPM OIF and 2,278,797 by UBS Oncology."}],"balance_after":6355717,"source":{"system":"sec-edgar","filing":"0001231919-25-000404","document":"form4-11042025_121157.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000404/form4-11042025_121157.xml","form_type":"4"}},{"id":1012193,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-29T23:21:10.000Z","date":"2025-10-29","kind":"sale","planned":true,"acquired":false,"shares":134240,"price":1.55,"value":208072.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 9,216 by AM LLC, 58,227 by BV 2014, 3,884 by BV 2014(B), 2,004 by AM BV2014, 12,823 by MPM OIF and 48,086 by UBS Oncology"},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.51 to $1.62 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 442,458 by AM LLC, 2,794,400 by BV 2014, 186,381 by BV 2014(B), 96,183 by AM BV2014, 613,293 by MPM OIF and 2,309,938 by UBS Oncology."}],"balance_after":6442653,"source":{"system":"sec-edgar","filing":"0001231919-25-000373","document":"form4-10292025_111002.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000373/form4-10292025_111002.xml","form_type":"4"}},{"id":1012192,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-29T23:21:10.000Z","date":"2025-10-28","kind":"sale","planned":true,"acquired":false,"shares":69068,"price":1.64,"value":113271.52,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 4,742 by AM LLC, 29,958 by BV 2014, 1,998 by BV 2014(B), 1,031 by AM BV2014, 6,598 by MPM OIF and 24,741 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.605 to $1.70 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 451,674 by AM LLC, 2,852,627 by BV 2014, 190,265 by BV 2014(B), 98,187 by AM BV2014, 626,116 by MPM OIF and 2,358,024 by UBS Oncology."}],"balance_after":6576893,"source":{"system":"sec-edgar","filing":"0001231919-25-000373","document":"form4-10292025_111002.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000373/form4-10292025_111002.xml","form_type":"4"}},{"id":1012191,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-29T23:21:10.000Z","date":"2025-10-27","kind":"sale","planned":true,"acquired":false,"shares":72709,"price":1.72,"value":125059.48,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 4,992 by MPM Asset Management LLC (\"AM LLC\"), 31,538 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 2,104 by MPM BioVentures 2014(B), L.P. (BV 2014(B), 1,085 MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 6,945 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\") and 26,045 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC and a manager of MPM OIF GP. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"shares","element":"transactionShares","label":"F3","text":"MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.675 to $1.82 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 456,416 by AM LLC, 2,882,585 by BV 2014, 192,263 by BV 2014(B), 99,218 by AM BV2014, 632,714 by MPM OIF and 2,382,765 by UBS Oncology."}],"balance_after":6645961,"source":{"system":"sec-edgar","filing":"0001231919-25-000373","document":"form4-10292025_111002.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191925000373/form4-10292025_111002.xml","form_type":"4"}},{"id":1147830,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":2,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":3,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":4,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2025-05-15T21:34:15.000Z","date":"2025-05-13","kind":"sale","planned":false,"acquired":false,"shares":1031931,"price":8.06,"value":8317363.86,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were sold as follows: 355,406 by MPM BioVentures 2014, L.P. (\"BV 2014\"),  22,386 by MPM BioVentures 2014 (B), L.P. (\"BV 2014(B)\"), 12,233 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 224,467 by MPM BioVentures 2018, L.P. (\"BV 2018\"), 11,267 by MPM BioVentures 2018(B), L.P. (\"BV 2018(B)\"), 4,432 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\") and 401,740 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV 2014 LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV 2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC."},{"field":"shares","element":"transactionShares","label":"F2","text":"MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.73 to $8.34 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held as follows: 1,189,174 by BV 2014, 74,903 by BV 2014(B), 40,931 by AM BV2014, 751,056 by BV 2018, 37,699 by BV 2018(B), 14,831 by AM BV2018 and 1,344,203 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":3452797,"source":{"system":"sec-edgar","filing":"0001415889-25-013252","document":"form4-05152025_090510.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000141588925013252/form4-05152025_090510.xml","form_type":"4"}},{"id":1163512,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2025-04-30T20:08:50.000Z","date":"2025-03-27","kind":"other","planned":false,"acquired":false,"shares":42842,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 27, 2025, the Reporting Persons exercised warrants to purchase an aggregate of 50,873 shares of the Company's Common Stock for $0.09 per share.  The Reporting Persons paid the exercise price on a cashless basis, resulting in the Company's withholding of 4,386 of the warrant shares to pay the exercise price and issuing the remaining 46,487 shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Immediately exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The warrants were held as follows: 17,023 by BV 2014, 1,135 by BV 2014(B), 585 by AM BV 2014, 5,355 by MPM OIF and 18,744 by UBS Oncology."}],"balance_after":0,"derivative":{"exercise_price":0.09,"expiration_date":"2025-08-13","underlying":"Common Stock","underlying_shares":42842},"source":{"system":"sec-edgar","filing":"0001415889-25-011569","document":"form4-04302025_080446.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000141588925011569/form4-04302025_080446.xml","form_type":"4"}},{"id":1163511,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2025-04-30T20:08:50.000Z","date":"2025-03-27","kind":"other","planned":false,"acquired":false,"shares":8031,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 27, 2025, the Reporting Persons exercised warrants to purchase an aggregate of 50,873 shares of the Company's Common Stock for $0.09 per share.  The Reporting Persons paid the exercise price on a cashless basis, resulting in the Company's withholding of 4,386 of the warrant shares to pay the exercise price and issuing the remaining 46,487 shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Immediately exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The warrants were held as follows:  3,647 by BV 2014, 243 by BV 2014(B), 125 by AM BV 2014 and 4,016 by UBS Oncology."}],"balance_after":0,"derivative":{"exercise_price":0.09,"expiration_date":"2025-04-09","underlying":"Common Stock","underlying_shares":8031},"source":{"system":"sec-edgar","filing":"0001415889-25-011569","document":"form4-04302025_080446.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000141588925011569/form4-04302025_080446.xml","form_type":"4"}},{"id":1163510,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-30T20:08:50.000Z","date":"2025-03-27","kind":"sale","planned":false,"acquired":false,"shares":4386,"price":1.05,"value":4605.3,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 27, 2025, the Reporting Persons exercised warrants to purchase an aggregate of 50,873 shares of the Company's Common Stock for $0.09 per share.  The Reporting Persons paid the exercise price on a cashless basis, resulting in the Company's withholding of 4,386 of the warrant shares to pay the exercise price and issuing the remaining 46,487 shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held as follows: 461,408 by AM LLC, 2,914,123 by BV 2014, 194,367 by BV 2014(B), 100,303 by AM BV2014, 639,659 by MPM OIF and 2,408,810 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":6718670,"source":{"system":"sec-edgar","filing":"0001415889-25-011569","document":"form4-04302025_080446.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000141588925011569/form4-04302025_080446.xml","form_type":"4"}},{"id":1163509,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM BioImpact LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69400,"kind":"organization","name":"MPM ASSET MANAGEMENT LLC","position":7,"cik":"0001263048","reported_name":"MPM ASSET MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-30T20:08:50.000Z","date":"2025-03-27","kind":"other","planned":false,"acquired":true,"shares":50873,"price":0.09,"value":4578.57,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 27, 2025, the Reporting Persons exercised warrants to purchase an aggregate of 50,873 shares of the Company's Common Stock for $0.09 per share.  The Reporting Persons paid the exercise price on a cashless basis, resulting in the Company's withholding of 4,386 of the warrant shares to pay the exercise price and issuing the remaining 46,487 shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held as follows: 461,408 by MPM Asset Management LLC (\"AM LLC\"), 2,915,905 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 194,486 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 100,365 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 640,121 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\") and 2,410,771 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC and a manager of MPM OIF GP. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"MPM BioImpact LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology.  Ansbert Gadicke is the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":6723056,"source":{"system":"sec-edgar","filing":"0001415889-25-011569","document":"form4-04302025_080446.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000141588925011569/form4-04302025_080446.xml","form_type":"4"}},{"id":1334310,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2479,"kind":"organization","name":"MPM BioVentures 2014, L.P.","position":1,"cik":"0001609492","reported_name":"MPM BioVentures 2014, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2480,"kind":"person","name":"EVNIN LUKE","position":2,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":3,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2482,"kind":"person","name":"Foley Todd","position":4,"cik":"0001473930","reported_name":"Foley Todd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2483,"kind":"organization","name":"MPM BioVentures 2014 (B), L.P.","position":5,"cik":"0001609493","reported_name":"MPM BioVentures 2014 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2484,"kind":"organization","name":"MPM Asset Management Investors BV2014 LLC","position":6,"cik":"0001609495","reported_name":"MPM Asset Management Investors BV2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2485,"kind":"organization","name":"MPM BioVentures 2014 LLC","position":7,"cik":"0001765021","reported_name":"MPM BioVentures 2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2486,"kind":"organization","name":"MPM BioVentures 2014 GP LLC","position":8,"cik":"0001765091","reported_name":"MPM BioVentures 2014 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2487,"kind":"organization","name":"MPM BIOVENTURES 2018 (B), L.P.","position":9,"cik":"0001729504","reported_name":"MPM BIOVENTURES 2018 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2488,"kind":"organization","name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","position":10,"cik":"0001734817","reported_name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-12-12T22:00:18.000Z","date":"2024-12-11","kind":"sale","planned":false,"acquired":false,"shares":21787,"price":20.23,"value":440751.01,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"The shares were sold as follows: 9,893 by BV 2014, 660 by BV 2014(B), 341 by AM BV2014, 10,153 by BV 2018, 540 by BV 2018(B) and 200 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Price represents the weighted average sale price of the shares sold. The sale price ranged from $20.01 to $20.595 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding\nthe number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are held as follows: 1,989,368 by BV 2014, 132,687 by BV 2014(B), 68,475 by AM BV2014, 2,041,721 by BV 2018, 108,515 by BV 2018(B) and 40,296 by AM BV2018."}],"balance_after":4381062,"source":{"system":"sec-edgar","filing":"0001415889-24-029141","document":"form4-12122024_051201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000141588924029141/form4-12122024_051201.xml","form_type":"4"}},{"id":1334309,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2479,"kind":"organization","name":"MPM BioVentures 2014, L.P.","position":1,"cik":"0001609492","reported_name":"MPM BioVentures 2014, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2480,"kind":"person","name":"EVNIN LUKE","position":2,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":3,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2482,"kind":"person","name":"Foley Todd","position":4,"cik":"0001473930","reported_name":"Foley Todd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2483,"kind":"organization","name":"MPM BioVentures 2014 (B), L.P.","position":5,"cik":"0001609493","reported_name":"MPM BioVentures 2014 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2484,"kind":"organization","name":"MPM Asset Management Investors BV2014 LLC","position":6,"cik":"0001609495","reported_name":"MPM Asset Management Investors BV2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2485,"kind":"organization","name":"MPM BioVentures 2014 LLC","position":7,"cik":"0001765021","reported_name":"MPM BioVentures 2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2486,"kind":"organization","name":"MPM BioVentures 2014 GP LLC","position":8,"cik":"0001765091","reported_name":"MPM BioVentures 2014 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2487,"kind":"organization","name":"MPM BIOVENTURES 2018 (B), L.P.","position":9,"cik":"0001729504","reported_name":"MPM BIOVENTURES 2018 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2488,"kind":"organization","name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","position":10,"cik":"0001734817","reported_name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-12-12T22:00:18.000Z","date":"2024-12-10","kind":"sale","planned":false,"acquired":false,"shares":22935,"price":20.77,"value":476359.95,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were sold as follows: 10,415 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 695 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 358 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 10 688 by MPM BioVentures 2018, L.P. (\"BV 2018\"), 568 by MPM BioVentures 2018 (B), L.P. (\"BV 2018(B)\") and 211 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV2014 LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Price represents the weighted average sale price of the shares sold. The sale price ranged from $20.356 to $21.315 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held as follows: 1,999,261 by BV 2014, 133,347 by BV 2014(B), 68,816 by AM BV2014, 2,051,874 by BV 2018, 109,055 by BV 2018(B) and 40,496 by AM BV2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."}],"balance_after":4402849,"source":{"system":"sec-edgar","filing":"0001415889-24-029141","document":"form4-12122024_051201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000141588924029141/form4-12122024_051201.xml","form_type":"4"}},{"id":1867668,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-05T20:35:42.000Z","date":"2023-06-01","kind":"other","planned":false,"acquired":false,"shares":3370982,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the \"Company\"), Adaptimmune Therapeutics plc (\"Parent\") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent (\"Merger Sub\"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the \"Merger Agreement\"), pursuant to which Merger Sub merged with and into the Company (the \"Merger\") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Effective Time, each issued and outstanding share of common stock of the Company (each, a \"Share\") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the \"Exchange Ratio\") American Depositary Shares of Parent (\"Parent ADS\") representing six ordinary shares of Parent (\"Parent Ordinary Shares\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares were held by UBS Oncology Impact Fund L.P. (\"UBS Oncology\"). BioImpact Capital LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. The reporting person is the managing partner of BioImpact and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-034336","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919123034336/doc4.xml","form_type":"4"}},{"id":1867667,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-05T20:35:42.000Z","date":"2023-06-01","kind":"other","planned":false,"acquired":false,"shares":3854963,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the \"Company\"), Adaptimmune Therapeutics plc (\"Parent\") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent (\"Merger Sub\"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the \"Merger Agreement\"), pursuant to which Merger Sub merged with and into the Company (the \"Merger\") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Effective Time, each issued and outstanding share of common stock of the Company (each, a \"Share\") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the \"Exchange Ratio\") American Depositary Shares of Parent (\"Parent ADS\") representing six ordinary shares of Parent (\"Parent Ordinary Shares\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares were held as follows: 3,056,272 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 203,846 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 110,859 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 421,070 by MPM SunStates Fund, L.P. (\"MPM SunStates\") and 62,916 by MPM Asset Management Investors Sunstates Fund LLC (\"AM SunStates\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B) and BV LLC is the manager of AM BV2014. MPM SunStates Fund GP LLC and MPM SunStates GP Managing Member LLC (\"SunStates GP\") are the direct and indirect general partners of MPM SunStates and SunStates GP is the manager of AM SunStates. The reporting person is a managing director of BV LLC and a member of SunStates GP and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-034336","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919123034336/doc4.xml","form_type":"4"}},{"id":1867666,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-05T20:35:42.000Z","date":"2023-06-01","kind":"other","planned":false,"acquired":false,"shares":304001,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the \"Company\"), Adaptimmune Therapeutics plc (\"Parent\") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent (\"Merger Sub\"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the \"Merger Agreement\"), pursuant to which Merger Sub merged with and into the Company (the \"Merger\") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Effective Time, each issued and outstanding share of common stock of the Company (each, a \"Share\") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the \"Exchange Ratio\") American Depositary Shares of Parent (\"Parent ADS\") representing six ordinary shares of Parent (\"Parent Ordinary Shares\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares were held by MPM Asset Management LLC (\"AM LLC\").  The reporting person is a member of AM LLC and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-034336","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919123034336/doc4.xml","form_type":"4"}},{"id":1880041,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Warrant (Right to Buy)","published_at":"2023-05-24T20:38:19.000Z","date":"2023-05-22","kind":"other","planned":false,"acquired":false,"shares":135508,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 22, 2023, MPM Asset Management LLC (\"AM LLC\") exercised warrants to purchase 178,269 shares of the Issuer's common stock for $0.74 a share. AM LLC paid the exercise price on a cashless basis, resulting in the Issuer's withholding of 70,170 of the warrant shares to satisfy the exercise price and issuing to AM LLC the remaining 108,099 shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by AM LLC.  The reporting person is a member of AM LLC and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":0.74,"exercise_date":"2017-12-06","expiration_date":"2027-12-05","underlying":"Common Stock","underlying_shares":135508},"source":{"system":"sec-edgar","filing":"0001209191-23-031888","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919123031888/doc4.xml","form_type":"4"}},{"id":1880040,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Warrant (Right To Buy)","published_at":"2023-05-24T20:38:19.000Z","date":"2023-05-22","kind":"other","planned":false,"acquired":false,"shares":42761,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 22, 2023, MPM Asset Management LLC (\"AM LLC\") exercised warrants to purchase 178,269 shares of the Issuer's common stock for $0.74 a share. AM LLC paid the exercise price on a cashless basis, resulting in the Issuer's withholding of 70,170 of the warrant shares to satisfy the exercise price and issuing to AM LLC the remaining 108,099 shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by AM LLC.  The reporting person is a member of AM LLC and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":0.74,"exercise_date":"2016-12-13","expiration_date":"2026-12-12","underlying":"Common Stock","underlying_shares":42761},"source":{"system":"sec-edgar","filing":"0001209191-23-031888","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919123031888/doc4.xml","form_type":"4"}},{"id":1880039,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-24T20:38:19.000Z","date":"2023-05-22","kind":"sale","planned":false,"acquired":false,"shares":70170,"price":1.88,"value":131919.6,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 22, 2023, MPM Asset Management LLC (\"AM LLC\") exercised warrants to purchase 178,269 shares of the Issuer's common stock for $0.74 a share. AM LLC paid the exercise price on a cashless basis, resulting in the Issuer's withholding of 70,170 of the warrant shares to satisfy the exercise price and issuing to AM LLC the remaining 108,099 shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by AM LLC.  The reporting person is a member of AM LLC and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":304001,"source":{"system":"sec-edgar","filing":"0001209191-23-031888","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919123031888/doc4.xml","form_type":"4"}},{"id":1880038,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-24T20:38:19.000Z","date":"2023-05-22","kind":"other","planned":false,"acquired":true,"shares":178269,"price":0.74,"value":131919.06,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 22, 2023, MPM Asset Management LLC (\"AM LLC\") exercised warrants to purchase 178,269 shares of the Issuer's common stock for $0.74 a share. AM LLC paid the exercise price on a cashless basis, resulting in the Issuer's withholding of 70,170 of the warrant shares to satisfy the exercise price and issuing to AM LLC the remaining 108,099 shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by AM LLC.  The reporting person is a member of AM LLC and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":374171,"source":{"system":"sec-edgar","filing":"0001209191-23-031888","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919123031888/doc4.xml","form_type":"4"}},{"id":2023205,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"Former Director"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-10T21:26:45.000Z","date":"2021-12-21","kind":"exercise","acquired":false,"shares":88824,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":4.3,"expiration_date":"2030-10-28","underlying":"Common Stock","underlying_shares":88824},"source":{"system":"sec-edgar","filing":"0001209191-23-008382","document":"doc5.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919123008382/doc5.xml","form_type":"5"}},{"id":2023204,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"Former Director"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-10T21:26:45.000Z","date":"2021-12-21","kind":"exercise","acquired":false,"shares":262114,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":4.3,"expiration_date":"2030-10-28","underlying":"Common Stock","underlying_shares":262114},"source":{"system":"sec-edgar","filing":"0001209191-23-008382","document":"doc5.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919123008382/doc5.xml","form_type":"5"}},{"id":2023203,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"Former Director"}}],"security":"Common Stock","published_at":"2023-02-10T21:26:45.000Z","date":"2021-12-21","kind":"exercise","acquired":true,"shares":350938,"price":4.3,"value":1509033.4,"ownership":{"direct":true},"balance_after":595489,"source":{"system":"sec-edgar","filing":"0001209191-23-008382","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919123008382/doc5.xml","form_type":"5"}},{"id":2199236,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-08-01T20:34:52.000Z","date":"2022-07-28","kind":"grant","acquired":true,"shares":3253796,"price":4.61,"value":14999999.56,"ownership":{"direct":false,"nature":"By ElevateBio LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 28, 2022, ElevateBio LLC (\"ElevateBio\") acquired 3,253,796 shares of the Issuer's Common Stock in a registered direct offering for a purchase price of $4.61 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by ElevateBio. The Reporting Person is a director of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":16674766,"source":{"system":"sec-edgar","filing":"0000899243-22-027167","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000089924322027167/doc4.xml","form_type":"4"}},{"id":2223196,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-23T22:22:01.000Z","date":"2022-06-22","kind":"grant","acquired":true,"shares":16475,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option represents a right to purchase a total of 16,475 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 22, 2023 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date."}],"balance_after":16475,"derivative":{"exercise_price":12.73,"expiration_date":"2032-06-21","underlying":"Common Stock","underlying_shares":16475},"source":{"system":"sec-edgar","filing":"0000899243-22-023771","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000089924322023771/doc4.xml","form_type":"4"}},{"id":2264174,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-19T20:27:20.000Z","date":"2022-05-17","kind":"grant","acquired":true,"shares":27500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable upon the earlier to occur of (i) May 17, 2023 and (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":27500,"derivative":{"exercise_price":4.6,"expiration_date":"2032-05-16","underlying":"Common Stock","underlying_shares":27500},"source":{"system":"sec-edgar","filing":"0000899243-22-018832","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000089924322018832/doc4.xml","form_type":"4"}},{"id":2317919,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-25T23:32:26.000Z","date":"2021-09-16","kind":"grant","acquired":true,"shares":7800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option represents a right to purchase a total of 7,800 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 25, 2022 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date."}],"balance_after":7800,"derivative":{"exercise_price":28.8,"expiration_date":"2031-09-15","underlying":"Common Stock","underlying_shares":7800},"source":{"system":"sec-edgar","filing":"0000899243-22-012375","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000089924322012375/doc4.xml","form_type":"4"}},{"id":2441902,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-06T21:12:23.000Z","date":"2022-01-05","kind":"sale","acquired":false,"shares":30347,"price":42.03,"value":1275484.41,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F14","text":"The shares were sold as follows: 10,804 by BV 2014, 372 by AM BV2014, 6,824 by BV 2018, 135 by AM BV2018 and 12,212 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.38 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F16","text":"The shares are held as follows: 1,544,580 by BV 2014, 97,289 by, 53,164 by AM BV2014, 975,523 by BV 2018, 48,966 by BV 2018(B), 19,263 by AM BV2018 and 1,745,943 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":4484728,"source":{"system":"sec-edgar","filing":"0001209191-22-002167","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919122002167/doc4.xml","form_type":"4"}},{"id":2441901,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-06T21:12:23.000Z","date":"2022-01-04","kind":"sale","acquired":false,"shares":12829,"price":46.47,"value":596163.63,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F11","text":"The shares were sold as follows: 4,590 by BV 2014, 154 by AM BV2014, 2,874 by  BV 2018, 53 by AM BV2018 and 5,158 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.025 to $46.965 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F13","text":"The shares are held as follows: 1,555,384 by BV 2014, 97,289 by BV 2014(B), 53,536 by AM BV2014, 982,347 by BV 2018, 48,966 by BV 2018(B), 19,398 by AM BV2018 and 1,758,155 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":4515075,"source":{"system":"sec-edgar","filing":"0001209191-22-002167","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919122002167/doc4.xml","form_type":"4"}},{"id":2441900,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-06T21:12:23.000Z","date":"2022-01-04","kind":"sale","acquired":false,"shares":11318,"price":45.32,"value":512931.76,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F8","text":"The shares were sold as follows: 4,050 by BV 2014, 133 by AM BV2014, 2,544 by  BV 2018, 41 by AM BV2018 and 4,550 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The shares are held as follows: 1,559,974 by BV 2014, 97,289 by BV 2014(B), 53,690 by AM BV2014, 985,221 by BV 2018, 48,966 by BV 2018(B), 19,451 by AM BV2018 and 1,763,313 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":4527904,"source":{"system":"sec-edgar","filing":"0001209191-22-002167","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919122002167/doc4.xml","form_type":"4"}},{"id":2441899,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-06T21:12:23.000Z","date":"2022-01-04","kind":"sale","acquired":false,"shares":32396,"price":43.2,"value":1399507.2,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"The shares were sold as follows: 11,534  by BV 2014, 390 by AM BV2014, 7,300 by BV 2018, 142 by AM BV2018 and 13,030 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.79 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are held as follows: 1,564,024 by BV 2014, 97,289 by BV 2014(B), 53,823 by AM BV2014, 987,765 by BV 2018, 48,966 by BV 2018(B), 19,492 by AM BV2018 and 1,767,863 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":4539222,"source":{"system":"sec-edgar","filing":"0001209191-22-002167","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919122002167/doc4.xml","form_type":"4"}},{"id":2441898,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-06T21:12:23.000Z","date":"2022-01-04","kind":"sale","acquired":false,"shares":158579,"price":42.05,"value":6668246.95,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"BioImpact Capital LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 56,414 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 1,959 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 35,653 by MPM BioVentures 2018, L.P. (\"BV 2018\"), 719 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\") and 63,834 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV 2014 LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV 2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.58 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held as follows: 1,575,558 by BV 2014, 97,289 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 54,213 by AM BV2014, 995,065 by BV 2018, 48,966 by MPM BioVentures 2018(B), L.P. (\"BV 2018(B)\"), 19,634 by AM BV2018 and 1,780,893 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":4571618,"source":{"system":"sec-edgar","filing":"0001209191-22-002167","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919122002167/doc4.xml","form_type":"4"}},{"id":2482712,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-07T23:33:54.000Z","date":"2021-12-07","kind":"sale","acquired":false,"shares":2499,"price":34.11,"value":85240.89,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F25","text":"The shares were sold as follows: 890 by BV 2014, 31 by AM BV2014, 562 by BV 2018, 11 by AM BV2018 and 1,005 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F26","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.875 to $34.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F27","text":"The shares are held as follows: 1,631,972 by BV 2014, 97,289 by BV 2014(B), 56,172  by AM BV2014, 1,030,718 by BV 2018, 48,966 by BV 2018(B), 20,353 by AM BV2018 and 1,844,727 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":4730197,"source":{"system":"sec-edgar","filing":"0001209191-21-068406","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121068406/doc4.xml","form_type":"4"}},{"id":2482711,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-07T23:33:54.000Z","date":"2021-12-07","kind":"sale","acquired":false,"shares":30059,"price":33.15,"value":996455.85,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F22","text":"The shares were sold as follows: 10,701 by BV 2014, 368 by AM BV2014, 6,759 by BV 2018, 134 by AM BV2018 and 12,097 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F23","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.84 to $33.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F24","text":"The shares are held as follows: 1,632,862 by BV 2014, 97,289 by BV 2014(B), 56,203 by AM BV2014, 1,031,280 by BV 2018, 48,966 by BV 2018(B), 20,364 by AM BV2018 and 1,845,732 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":4732696,"source":{"system":"sec-edgar","filing":"0001209191-21-068406","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121068406/doc4.xml","form_type":"4"}},{"id":2482710,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-07T23:33:54.000Z","date":"2021-12-06","kind":"sale","acquired":false,"shares":100,"price":35.04,"value":3504.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F20","text":"The shares were sold as follows: 35 by BV 2014, 2 by AM BV2014, 22 by BV 2018, 1 by AM BV2018 and 40 by UBS Oncology."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F21","text":"The shares are held as follows: 1,643,563 by BV 2014, 97,289 by BV 2014(B), 56,571 by AM BV2014, 1,038,039 by BV 2018, 48,966 by BV 2018(B), 20,498 by AM BV2018 and 1,857,829 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":4762755,"source":{"system":"sec-edgar","filing":"0001209191-21-068406","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121068406/doc4.xml","form_type":"4"}},{"id":2482709,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-07T23:33:54.000Z","date":"2021-12-06","kind":"sale","acquired":false,"shares":850,"price":34.08,"value":28968.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F17","text":"The shares were sold as follows: 303 by BV 2014, 10 by AM BV2014, 191 by BV 2018, 4 by AM BV2018 and 342 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F18","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.00 to $34.125 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F19","text":"The shares are held as follows: 1,643,598 by BV 2014, 97,289 by BV 2014(B), 56,573 by AM BV2014, 1,038,061 by BV 2018, 48,966 by BV 2018(B), 20,499 by AM BV2018 and 1,857,869 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":4762855,"source":{"system":"sec-edgar","filing":"0001209191-21-068406","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121068406/doc4.xml","form_type":"4"}},{"id":2482708,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-07T23:33:54.000Z","date":"2021-12-06","kind":"sale","acquired":false,"shares":1960,"price":33.57,"value":65797.2,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F14","text":"The shares were sold as follows: 698 by BV 2014, 24 by AM BV2014, 441 by BV 2018, 8 by AM BV2018 and 789 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.99 to $33.98 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F16","text":"The shares are held as follows: 1,643,901 by BV 2014, 97,289 by, 56,583 by AM BV2014, 1,038,252 by BV 2018, 48,966 by BV 2018(B), 20,503 by AM BV2018 and 1,858,211 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":4763705,"source":{"system":"sec-edgar","filing":"0001209191-21-068406","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121068406/doc4.xml","form_type":"4"}},{"id":2482707,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-07T23:33:54.000Z","date":"2021-12-06","kind":"sale","acquired":false,"shares":14173,"price":32.35,"value":458496.55,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F11","text":"The shares were sold as follows: 5,046 by BV 2014, 173 by AM BV2014, 3,187 by  BV 2018, 63 by AM BV2018 and 5,704 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.98 to $32.975 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F13","text":"The shares are held as follows: 1,644,599 by BV 2014, 97,289 by BV 2014(B), 56,607 by AM BV2014, 1,038,693 by BV 2018, 48,966 by BV 2018(B), 20,511 by AM BV2018 and 1,859,000 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":4765665,"source":{"system":"sec-edgar","filing":"0001209191-21-068406","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121068406/doc4.xml","form_type":"4"}},{"id":2482706,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-07T23:33:54.000Z","date":"2021-12-03","kind":"sale","acquired":false,"shares":300,"price":36.26,"value":10878.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 107 by BV 2014, 4 by AM BV2014, 67 by  BV 2018, 1 by AM BV2018 and 121 by UBS Oncology."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The shares are held as follows: 1,649,645 by BV 2014, 97,289 by BV 2014(B), 56,780 by AM BV2014, 1,041,880 by BV 2018, 48,966 by BV 2018(B), 20,574 by AM BV2018 and 1,864,704 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":4779838,"source":{"system":"sec-edgar","filing":"0001209191-21-068406","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121068406/doc4.xml","form_type":"4"}},{"id":2482705,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-07T23:33:54.000Z","date":"2021-12-03","kind":"sale","acquired":false,"shares":4047,"price":35.44,"value":143425.68,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 1,441 by BV 2014, 50 by AM BV2014, 910 by BV 2018, 18 by AM BV2018 and 1,628 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.15 to $36.06 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 1,649,752 by BV 2014, 97,289 by BV 2014(B), 56,784 by AM BV2014, 1,041,947 by BV 2018, 48,966 by BV 2018(B), 20,575 by AM BV2018 and 1,864,825 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":4780138,"source":{"system":"sec-edgar","filing":"0001209191-21-068406","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121068406/doc4.xml","form_type":"4"}},{"id":2482704,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-07T23:33:54.000Z","date":"2021-12-03","kind":"sale","acquired":false,"shares":29402,"price":34.68,"value":1019661.36,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F2","text":"BioImpact Capital LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."},{"field":"shares","element":"transactionShares","label":"F3","text":"The shares were sold as follows: 10,467 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 359  by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 6,612 by MPM BioVentures 2018, L.P. (\"BV 2018\"), 131 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\") and 11,833 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV 2014 LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV 2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.15 to $35.135 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 1,651,193 by BV 2014, 97,289 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 56,834 by AM BV2014, 1,042,857 by BV 2018, 48,966 by MPM BioVentures 2018(B), L.P. (\"BV 2018(B)\"), 20,593 by AM BV2018 and 1,866,453 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":4784185,"source":{"system":"sec-edgar","filing":"0001209191-21-068406","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121068406/doc4.xml","form_type":"4"}},{"id":2489265,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-02T23:53:00.000Z","date":"2021-12-02","kind":"sale","acquired":false,"shares":12434,"price":34.83,"value":433076.22,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F21","text":"The shares were sold as follows: 4,427 by BV 2014, 152 by AM BV2014, 2,796 by BV 2018, 55 by AM BV2018 and 5,004 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F22","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.25 to $35.14 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F23","text":"The shares are held as follows: 1,661,660 by BV 2014, 97,289 by BV 2014(B), 57,193 by AM BV2014, 1,049,469 by BV 2018, 48,966 by BV 2018(B), 20,724 by AM BV2018 and 1,878,286 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":4813587,"source":{"system":"sec-edgar","filing":"0001209191-21-067705","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121067705/doc4.xml","form_type":"4"}},{"id":2489264,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-02T23:53:00.000Z","date":"2021-12-02","kind":"sale","acquired":false,"shares":49796,"price":33.74,"value":1680117.04,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F18","text":"The shares were sold as follows: 17,728 by BV 2014, 611 by AM BV2014, 11,197 by BV 2018, 221 by AM BV2018 and 20,039 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F19","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.19 to $34.17 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F20","text":"The shares are held as follows: 1,666,087 by BV 2014, 97,289 by BV 2014(B), 57,345 by AM BV2014, 1,052,265 by BV 2018, 48,966 by BV 2018(B), 20,779 by AM BV2018 and 1,883,290 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":4826021,"source":{"system":"sec-edgar","filing":"0001209191-21-067705","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121067705/doc4.xml","form_type":"4"}},{"id":2489263,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-02T23:53:00.000Z","date":"2021-12-01","kind":"sale","acquired":false,"shares":1500,"price":35.34,"value":53010.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F15","text":"The shares were sold as follows: 534 by BV 2014, 18 by AM BV2014, 337 by BV 2018, 7 by AM BV2018 and 604  by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F16","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.30 to $35.77 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F17","text":"The shares are held as follows: 1,683,815 by BV 2014, 97,289 by, 57,956 by AM BV2014, 1,063,462 by BV 2018, 48,966 by BV 2018(B), 21,000 by AM BV2018 and 1,903,329 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":4875817,"source":{"system":"sec-edgar","filing":"0001209191-21-067705","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121067705/doc4.xml","form_type":"4"}},{"id":2489262,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-02T23:53:00.000Z","date":"2021-12-01","kind":"sale","acquired":false,"shares":9131,"price":34.61,"value":316023.91,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F12","text":"The shares were sold as follows: 3,251 by BV 2014, 112 by AM BV2014, 2,053 by  BV 2018, 41 by AM BV2018 and 3,674 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.30 to $35.17 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F14","text":"The shares are held as follows: 1,684,349 by BV 2014, 97,289 by BV 2014(B), 57,974 by AM BV2014, 1,063,799 by BV 2018, 48,966 by BV 2018(B), 21,007 by AM BV2018 and 1,903,933 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":4877317,"source":{"system":"sec-edgar","filing":"0001209191-21-067705","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121067705/doc4.xml","form_type":"4"}},{"id":2489261,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-02T23:53:00.000Z","date":"2021-12-01","kind":"sale","acquired":false,"shares":10111,"price":33.82,"value":341954.02,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 3,600 by BV 2014, 124 by AM BV2014, 2,274 by  BV 2018, 44  by AM BV2018 and 4,069 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.26 to $34.22 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 1,687,600 by BV 2014, 97,289 by BV 2014(B), 58,086 by AM BV2014, 1,065,852 by BV 2018, 48,966 by BV 2018(B), 21,048 by AM BV2018 and 1,907,607 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":4886448,"source":{"system":"sec-edgar","filing":"0001209191-21-067705","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121067705/doc4.xml","form_type":"4"}},{"id":2489260,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-02T23:53:00.000Z","date":"2021-11-30","kind":"sale","acquired":false,"shares":46992,"price":35.19,"value":1653648.48,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 16,733 by BV 2014, 576 by AM BV2014, 10,569 by BV 2018, 198 by AM BV2018 and 18,916 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.93 to $35.465 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 1,691,200 by BV 2014, 97,289 by BV 2014(B), 58,210 by AM BV2014, 1,068,126 by BV 2018, 48,966 by BV 2018(B), 21,092 by AM BV2018 and 1,911,676 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":4896559,"source":{"system":"sec-edgar","filing":"0001209191-21-067705","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121067705/doc4.xml","form_type":"4"}},{"id":2489259,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-02T23:53:00.000Z","date":"2021-11-30","kind":"sale","acquired":false,"shares":9809,"price":34.62,"value":339587.58,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 3,494 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 120 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 2,206 by MPM BioVentures 2018, L.P. (\"BV 2018\"), 41 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\") and 3,948 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV 2014 LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV 2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC."},{"field":"shares","element":"transactionShares","label":"F3","text":"BioImpact Capital LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.93 to $34.92 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 1,707,933 by BV 2014, 97,289 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 58,786 by AM BV2014, 1,078,695 by BV 2018, 48,966 by MPM BioVentures 2018(B), L.P. (\"BV 2018(B)\"), 21,290 by AM BV2018 and 1,930,592 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":4943551,"source":{"system":"sec-edgar","filing":"0001209191-21-067705","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121067705/doc4.xml","form_type":"4"}},{"id":2492304,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-30T21:49:31.000Z","date":"2021-11-29","kind":"sale","acquired":false,"shares":500,"price":35.37,"value":17685.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F12","text":"The shares were sold as follows: 178 by BV 2014, 6 by AM BV2014, 112 by  BV 2018, 2 by AM BV2018 and 202 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.125 to $35.67 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F14","text":"The shares are held as follows: 1,711,427 by BV 2014, 97,289 by BV 2014(B), 58,906 by AM BV2014, 1,080,901 by BV 2018, 48,966 by BV 2018(B), 21,331 by AM BV2018 and 1,934,540 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":4953360,"source":{"system":"sec-edgar","filing":"0001209191-21-067146","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121067146/doc4.xml","form_type":"4"}},{"id":2492303,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-30T21:49:31.000Z","date":"2021-11-29","kind":"sale","acquired":false,"shares":16856,"price":34.46,"value":580857.76,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 6,001 by BV 2014, 207 by AM BV2014, 3,790 by  BV 2018, 75 by AM BV2018 and 6,783 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.06 to $34.86  inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 1,711,605 by BV 2014, 97,289 by BV 2014(B), 58,912 by AM BV2014, 1,081,013 by BV 2018, 48,966 by BV 2018(B), 21,333 by AM BV2018 and 1,934,742 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":4953860,"source":{"system":"sec-edgar","filing":"0001209191-21-067146","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121067146/doc4.xml","form_type":"4"}},{"id":2492302,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-30T21:49:31.000Z","date":"2021-11-26","kind":"sale","acquired":false,"shares":10258,"price":36.03,"value":369595.74,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 3,652 by BV 2014, 126 by AM BV2014, 2,306 by BV 2018, 45 by AM BV2018 and 4,129 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.92 to $36.39 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 1,717,606 by BV 2014, 97,289 by BV 2014(B), 59,119 by AM BV2014, 1,084,803 by BV 2018, 48,966 by BV 2018(B), 21,408 by AM BV2018 and 1,941,525 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":4970716,"source":{"system":"sec-edgar","filing":"0001209191-21-067146","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121067146/doc4.xml","form_type":"4"}},{"id":2492301,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-30T21:49:31.000Z","date":"2021-11-26","kind":"sale","acquired":false,"shares":10952,"price":35.49,"value":388686.48,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 3,899 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 134 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 2,463 by MPM BioVentures 2018, L.P. (\"BV 2018\"), 49 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\") and 4,407 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV 2014 LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV 2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC."},{"field":"shares","element":"transactionShares","label":"F3","text":"BioImpact Capital LLC (\"BioImpact\") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.915 to $35.91 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 1,721,258 by BV 2014, 97,289 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 59,245  by AM BV2014, 1,087,109 by BV 2018, 48,966 by MPM BioVentures 2018(B), L.P. (\"BV 2018(B)\"), 21,453 by AM BV2018 and 1,945,654 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":4980974,"source":{"system":"sec-edgar","filing":"0001209191-21-067146","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121067146/doc4.xml","form_type":"4"}},{"id":2496205,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-24T23:38:10.000Z","date":"2021-11-24","kind":"sale","acquired":false,"shares":21965,"price":37.02,"value":813144.3,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F24","text":"The shares were sold as follows: 7,820 by BV 2014, 269 by AM BV2014, 4,939 by BV 2018, 98 by AM BV2018 and 8,839 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F25","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.85 to $37.27 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F26","text":"The shares are held as follows: 1,725,157 by BV 2014, 97,289 by BV 2014(B), 59,379 by AM BV2014, 1,089,572 by BV 2018, 48,966 by BV 2018(B), 21,502 by AM BV2018 and 1,950,061 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":4991926,"source":{"system":"sec-edgar","filing":"0001209191-21-066854","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121066854/doc4.xml","form_type":"4"}},{"id":2496204,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-24T23:38:10.000Z","date":"2021-11-24","kind":"sale","acquired":false,"shares":30696,"price":36.05,"value":1106590.8,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F21","text":"The shares were sold as follows: 10,929 by BV 2014, 376 by AM BV2014, 6,902 by BV 2018, 136 by AM BV2018 and 12,353 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F22","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.83 to $36.81 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F23","text":"The shares are held as follows: 1,732,977 by BV 2014, 97,289 by BV 2014(B), 59,648 by AM BV2014, 1,094,511 by BV 2018, 48,966 by BV 2018(B), 21,600 by AM BV2018 and 1,958,900 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":5013891,"source":{"system":"sec-edgar","filing":"0001209191-21-066854","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121066854/doc4.xml","form_type":"4"}},{"id":2496203,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-24T23:38:10.000Z","date":"2021-11-24","kind":"sale","acquired":false,"shares":8147,"price":35.2,"value":286774.4,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F18","text":"The shares were sold as follows: 2,900 by BV 2014, 100 by AM BV2014, 1,832 by BV 2018, 36 by AM BV2018 and 3,279 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F19","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.82 to $35.78 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F20","text":"The shares are held as follows: 1,743,906 by BV 2014, 97,289 by BV 2014(B), 60,024 by AM BV2014, 1,101,413 by BV 2018, 48,966 by BV 2018(B), 21,736 by AM BV2018 and 1,971,253 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":5044587,"source":{"system":"sec-edgar","filing":"0001209191-21-066854","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121066854/doc4.xml","form_type":"4"}},{"id":2496202,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-24T23:38:10.000Z","date":"2021-11-23","kind":"sale","acquired":false,"shares":600,"price":36.5,"value":21900.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F15","text":"The shares were sold as follows: 214 by BV 2014, 7 by AM BV2014, 135 by  BV 2018, 3 by AM BV2018 and 241 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F16","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.48 to $36.52 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F17","text":"The shares are held as follows: 1,746,806  by BV 2014, 97,289 by BV 2014(B), 60,124 by AM BV2014, 1,103,245 by BV 2018, 48,966 by BV 2018(B), 21,772 by AM BV2018 and 1,974,532 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":5052734,"source":{"system":"sec-edgar","filing":"0001209191-21-066854","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121066854/doc4.xml","form_type":"4"}},{"id":2496201,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-24T23:38:10.000Z","date":"2021-11-23","kind":"sale","acquired":false,"shares":32876,"price":36.21,"value":1190439.96,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F12","text":"The shares were sold as follows: 11,704 by BV 2014, 403 by AM BV2014, 7,392 by  BV 2018, 146 by AM BV2018 and 13,231  by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.46 to $36.45 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F14","text":"The shares are held as follows: 1,747,020 by BV 2014, 97,289 by BV 2014(B), 60,131 by AM BV2014, 1,103,380 by BV 2018, 48,966 by BV 2018(B), 21,775 by AM BV2018 and 1,974,773 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":5053334,"source":{"system":"sec-edgar","filing":"0001209191-21-066854","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121066854/doc4.xml","form_type":"4"}},{"id":2496200,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-24T23:38:10.000Z","date":"2021-11-22","kind":"sale","acquired":false,"shares":19758,"price":37.81,"value":747049.98,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 7,034 by BV 2014, 242 by AM BV2014, 4,443 by BV 2018, 88 by AM BV2018 and 7,951 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.58 to $38.16 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 1,758,724 by BV 2014, 97,289 by BV 2014(B), 60,534 by AM BV2014, 1,110,772 by BV 2018, 48,966 by BV 2018(B), 21,921 by AM BV2018 and 1,988,004 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":5086210,"source":{"system":"sec-edgar","filing":"0001209191-21-066854","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121066854/doc4.xml","form_type":"4"}},{"id":2496199,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"BioImpact Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-24T23:38:10.000Z","date":"2021-11-22","kind":"sale","acquired":false,"shares":15575,"price":37.16,"value":578767.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 5,545 by BV 2014, 191 by AM BV2014, 3,502 by BV 2018, 69 by AM BV2018 and 6,268 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.58 to $37.555 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 1,765,758 by BV 2014, 97,289 by, 60,776 by AM BV2014, 1,115,215 by BV 2018, 48,966 by BV 2018(B), 22,009 by AM BV2018 and 1,995,955 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":5105986,"source":{"system":"sec-edgar","filing":"0001209191-21-066854","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121066854/doc4.xml","form_type":"4"}}],"next_cursor":"2021-11-24T23:38:10.000000Z,2496199"}